Whitehawk Therapeutics, Inc.(WHWK)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

WHWK Whitehawk Therapeutics, Inc.

盘后交易 09-04 19:03:41 EDT

4.60

-0.03

-0.65%

盘后4.60

+0.000.00%

16:10 EDT

最高4.65	最低4.53	成交量17.81万
今开4.59	昨收4.63	日振幅2.59%
总市值2.62亿	流通市值1.32亿	总股本5,701万
成交额81.33万	换手率0.62%	流通股本2,874万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"WHWK","market":"US","secType":"STK","nameCN":"Whitehawk Therapeutics, Inc.","latestPrice":4.6,"timestamp":1788552000000,"preClose":4.63,"halted":0,"volume":178140,"hourTrading":{"tag":"盘后","latestPrice":4.6,"preClose":4.6,"latestTime":"16:10 EDT","volume":1837,"amount":8450.199999999999,"timestamp":1788552604971,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.006479481641468736,"floatShares":28743300,"shares":57009000,"eps":-1.1137,"marketStatus":"盘后交易","change":-0.03,"latestTime":"09-04 19:03:41 EDT","open":4.59,"high":4.65,"low":4.53,"amount":813284,"amplitude":0.025918,"askPrice":5,"askSize":1000,"bidPrice":4.5,"bidSize":400,"shortable":3,"etf":0,"ttmEps":-1.1137,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1788566400000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":4.63,"postHourTrading":{"tag":"盘后","latestPrice":4.6,"preClose":4.6,"latestTime":"16:10 EDT","volume":1837,"amount":8450.199999999999,"timestamp":1788552604971,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.869682,"impliedVol":1.3921,"impliedVolPercentile":0.4841},"requestUrl":"/m/hq/s/WHWK","defaultTab":"news","newsList":[{"id":"1158445450","title":"百奥赛图与Whitehawk Therapeutics达成协议，将获得首付款、里程碑付款及个位数低段特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1158445450","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158445450?lang=zh_cn&edition=full","pubTime":"2026-07-07 20:06","pubTimestamp":1783425966,"startTime":"0","endTime":"0","summary":"根据最新协议，百奥赛图将向Whitehawk Therapeutics授予特定靶点抗体药物的独家授权。作为回报，百奥赛图有资格获得一笔可观的首付款，以及未来基于临床开发、监管审批和商业化进展的里程碑付款。此外，协议还规定，百奥赛图将在产品成功上市后，获得个位数低段的全球销售分层特许权使用费。此项合作结合了百奥赛图在基因编辑与抗体发现平台方面的优势，以及Whitehawk Therapeutics在肿瘤免疫治疗领域的研发专长。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK0216","688796","WHWK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198512367","title":"百奥赛图与Whitehawk Therapeutics达成全球合作，共同开发双特异性抗体ADC","url":"https://stock-news.laohu8.com/highlight/detail?id=1198512367","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198512367?lang=zh_cn&edition=full","pubTime":"2026-07-07 20:02","pubTimestamp":1783425761,"startTime":"0","endTime":"0","summary":"百奥赛图与Whitehawk Therapeutics宣布建立全球合作关系，双方将携手推进双特异性抗体药物偶联物的开发。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK0216","WHWK","688796"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112660145","title":"WhiteHawk Therapeutics提交SEC文件 现有股东拟发售及转售至多2232万股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1112660145","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112660145?lang=zh_cn&edition=full","pubTime":"2026-05-30 04:19","pubTimestamp":1780085958,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会（SEC）的文件，生物技术公司WhiteHawk Therapeutics已登记由售股股东发售及转售最多2232万股普通股。此举意味着现有股东可能在未来一段时间内，根据市场情况逐步出售其持有的公司股份。此类备案通常为后续的股票销售铺平道路，但具体出售的时间、价格和数量将由股东自行决定。市场参与者将密切关注此举可能对股票流动性和股价产生的影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","WHWK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152000750","title":"WhiteHawk Therapeutics通过新期权协议扩展ADC管线，引入Cpt113连接子-载荷","url":"https://stock-news.laohu8.com/highlight/detail?id=1152000750","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152000750?lang=zh_cn&edition=full","pubTime":"2026-05-22 05:05","pubTimestamp":1779397515,"startTime":"0","endTime":"0","summary":"WhiteHawk Therapeutics, Inc. 已签署一项新的期权协议，旨在将其抗体偶联药物（ADC）研发管线进一步扩展。根据协议内容，该公司获得了使用Cpt113连接子-载荷技术平台的选择权。此举标志着WhiteHawk在强化其ADC产品组合方面迈出了关键一步，为其未来在肿瘤治疗领域的创新药物开发提供了新的技术工具和战略灵活性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","WHWK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130402233","title":"WhiteHawk Therapeutics Q4运营亏损2488.7万美元，远逊于IBES预估的15.4万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1130402233","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130402233?lang=zh_cn&edition=full","pubTime":"2026-03-12 20:01","pubTimestamp":1773316871,"startTime":"0","endTime":"0","summary":"WhiteHawk Therapeutics, Inc.最新公布的第四季度财务数据显示，其运营状况令人担忧。报告期内，公司运营收入为亏损2488.7万美元，这一数字与市场研究机构IBES此前预估的15.4万美元盈利形成了巨大反差，凸显出公司在核心业务上的盈利能力面临严峻挑战。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WHWK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.whitehawktx.com","stockEarnings":[{"period":"1week","weight":-0.0493},{"period":"1month","weight":0.1184},{"period":"3month","weight":0.1157},{"period":"6month","weight":0.2347},{"period":"1year","weight":1.558},{"period":"ytd","weight":0.9132}],"compareEarnings":[{"period":"1week","weight":0.0027},{"period":"1month","weight":0.0024},{"period":"3month","weight":0.0483},{"period":"6month","weight":0.1499},{"period":"1year","weight":0.2011},{"period":"ytd","weight":0.1338}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Whitehawk Therapeutics, Inc.于2007年11月16日在特拉华州成立。该公司是一家临床阶段的生物制药公司，为基因定义的癌症开发精准疗法。该公司的主要目标是为mTOR通路驱动因子变化的癌症患者带来转化疗法，例如TSC1或TSC2基因的变化，而mTOR抑制剂由于药理学、有效药物递送、安全性或有效性问题而没有或不能得到有效利用。Aadi的主要产品是FYARROTM，这是一种mTOR抑制剂，可与人类蛋白质结合，并显示出更高的肿瘤积累、更大的mTOR靶点抑制和增强的肿瘤生长抑制。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.171513},{"month":2,"riseRate":0.375,"avgChangeRate":0.003987},{"month":3,"riseRate":0.125,"avgChangeRate":-0.201274},{"month":4,"riseRate":0.5,"avgChangeRate":0.004245},{"month":5,"riseRate":0.875,"avgChangeRate":0.189092},{"month":6,"riseRate":0.25,"avgChangeRate":-0.06443},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.040304},{"month":8,"riseRate":0.666667,"avgChangeRate":0.048238},{"month":9,"riseRate":0.666667,"avgChangeRate":0.004989},{"month":10,"riseRate":0.125,"avgChangeRate":-0.092738},{"month":11,"riseRate":0.625,"avgChangeRate":0.077853},{"month":12,"riseRate":0.5,"avgChangeRate":-0.084464}],"exchange":"NASDAQ","name":"Whitehawk Therapeutics, Inc.","nameEN":"Whitehawk Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Whitehawk Therapeutics, Inc.(WHWK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Whitehawk Therapeutics, Inc.(WHWK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Whitehawk Therapeutics, Inc.,WHWK,Whitehawk Therapeutics, Inc.股票,Whitehawk Therapeutics, Inc.股票老虎,Whitehawk Therapeutics, Inc.股票老虎国际,Whitehawk Therapeutics, Inc.行情,Whitehawk Therapeutics, Inc.股票行情,Whitehawk Therapeutics, Inc.股价,Whitehawk Therapeutics, Inc.股市,Whitehawk Therapeutics, Inc.股票价格,Whitehawk Therapeutics, Inc.股票交易,Whitehawk Therapeutics, Inc.股票购买,Whitehawk Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Whitehawk Therapeutics, Inc.(WHWK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Whitehawk Therapeutics, Inc.(WHWK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}